Immunovant (IMVT) Stock Forecast & Price Target

$34.03

+0.41 (+1.22%)

(As of 09/6/2024 ET)

Immunovant - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 15 Analyst Ratings

Based on 15 Wall Street analysts who have issued ratings for Immunovant in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 15 have given a buy rating for IMVT.

Consensus Price Target

$48.40
42.23% Upside

High Forecast	$57.00
Average Forecast	$48.40
Low Forecast	$40.00

According to the 15 analysts' twelve-month price targets for Immunovant, the average price target is $48.40. The highest price target for IMVT is $57.00, while the lowest price target for IMVT is $40.00. The average price target represents a forecasted upside of 42.23% from the current price of $34.03.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	15 Buy rating(s)	17 Buy rating(s)	11 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$48.40	$49.40	$48.75	$27.92
Forecasted Upside	42.23% Upside	41.76% Upside	40.53% Upside	44.39% Upside

Get Immunovant Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Why billionaires are wiring money to abandoned towns

A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution.

Click here for my exclusive video

IMVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immunovant Stock vs. The Competition

Type	Immunovant	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	42.23% Upside	1,207.57% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/13/2024	UBS Group 4 of 5 stars		Lower Target	Buy ➝ Buy	$42.00 ➝ $41.00	+37.45%
8/8/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$51.00 ➝ $46.00	+65.17%
8/7/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
6/3/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$50.00 ➝ $46.00	+81.17%
5/30/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$51.00 ➝ $51.00	+72.47%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$48.00	+47.69%
Get the Latest News and Ratings for IMVT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.
3/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+58.73%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$55.00	+45.50%
12/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$49.00 ➝ $51.00	+31.61%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+25.69%
10/24/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$28.00 ➝ $57.00	+64.74%
9/27/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $48.00	+14.75%
9/27/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$33.00 ➝ $50.00	+25.13%
9/27/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$33.00 ➝ $48.00	+20.12%
9/26/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$40.00	+7.79%
7/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$28.00 ➝ $34.00	+47.00%
7/10/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Barcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
2/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$14.00 ➝ $21.00	+18.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:10 PM ET.

IMVT Forecast - Frequently Asked Questions

What is Immunovant's forecast for 2024?: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunovant is $48.40, with a high forecast of $57.00 and a low forecast of $40.00.
Should I buy or sell Immunovant stock right now?: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares.
Does Immunovant's stock price have much upside?: According to analysts, Immunovant's stock has a predicted upside of 41.76% based on their 12-month stock forecasts.
What analysts cover Immunovant?: Immunovant has been rated by research analysts at Cantor Fitzgerald, JPMorgan Chase & Co., and UBS Group in the past 90 days.
Do Wall Street analysts like Immunovant more than its competitors?: Analysts like Immunovant more than other "medical" companies. The consensus rating for Immunovant is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMVT compares to other companies.